[The efficacy of membrane-stabilizing therapy in bronchial asthma]

Lipid peroxidation was studied in 65 bronchial asthma patients aged 23-56 in aggravation of their disease and after differential therapy. Conventional treatment proved unable to correct either enhanced lipid peroxidation (LPO) or weak antioxidant defense (AOD), whereas the addition to the treatment program of membrano-stabilizers (actovegin, lipostabil) contributed to LPO and AOD normalization, improved bronchial patency and, eventually, produced early remission.